Robert W. Baird Has Lowered Expectations for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its price target dropped by equities researchers at Robert W. Baird from $231.00 to $225.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s price target would indicate a potential upside of 14.52% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. The Goldman Sachs Group upgraded Danaher from a “neutral” rating to a “buy” rating and set a $260.00 price target on the stock in a research report on Friday, March 21st. Stifel Nicolaus upgraded shares of Danaher from a “hold” rating to a “buy” rating and set a $260.00 target price for the company in a research report on Friday, March 14th. Citigroup reiterated a “buy” rating on shares of Danaher in a research report on Monday, April 7th. Wells Fargo & Company lowered their price objective on shares of Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, Barclays raised their target price on Danaher from $205.00 to $215.00 and gave the company an “overweight” rating in a report on Tuesday. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $264.40.

Danaher Trading Up 0.1 %

Shares of Danaher stock opened at $196.48 on Wednesday. Danaher has a 52-week low of $171.00 and a 52-week high of $281.70. The stock has a market cap of $140.43 billion, a PE ratio of 37.21, a PEG ratio of 2.66 and a beta of 0.86. The firm has a 50-day moving average of $201.01 and a 200-day moving average of $225.07. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping the consensus estimate of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. As a group, sell-side analysts forecast that Danaher will post 7.63 EPS for the current year.

Insider Activity

In related news, SVP Brian W. Ellis sold 5,700 shares of the company’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 11.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Kentucky Retirement Systems Insurance Trust Fund lifted its holdings in Danaher by 11.6% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 21,233 shares of the conglomerate’s stock valued at $4,874,000 after buying an additional 2,202 shares during the period. ORG Partners LLC raised its position in shares of Danaher by 1,212.8% in the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after acquiring an additional 2,559 shares in the last quarter. Generate Investment Management Ltd acquired a new position in shares of Danaher in the 4th quarter valued at about $8,044,000. Compass Capital Management Inc. boosted its position in shares of Danaher by 4.8% during the 4th quarter. Compass Capital Management Inc. now owns 237,922 shares of the conglomerate’s stock valued at $54,615,000 after purchasing an additional 10,994 shares in the last quarter. Finally, Channing Global Advisors LLC increased its holdings in Danaher by 42.8% in the fourth quarter. Channing Global Advisors LLC now owns 5,666 shares of the conglomerate’s stock worth $1,301,000 after purchasing an additional 1,698 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.